Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Nov 22;83(11):1454–1461. doi: 10.1054/bjoc.2000.1492

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

E Tartour 1,2, M Mehtali 3, X Sastre-Garau 1, I Joyeux 1, C Mathiot 1, J M Pleau 1, P Squiban 3, C Rochlitz 4, M Courtney 3, P Jantscheff 4, R Herrmann 4, P Pouillart 5, W H Fridman 1,2, T Dorval 5
PMCID: PMC2363414  PMID: 11076653

Abstract

Various studies have emphasized an immunodepression state observed at the tumour site. To reverse this defect and based upon animal studies, we initiated a phase I clinical trial of gene therapy in which various doses of xenogeneic monkey fibroblasts (Vero cells) genetically engineered to produce human IL-2 were administered intratumorally in 8 patients with metastatic solid tumours. No severe adverse effect was observed in the 8 patients analysed during this clinical trial even in the highest dose (5 ¥ 107 cells) group. This absence of toxicity seems to be associated with rapid elimination of Vero-IL-2 cells from the organism. Indeed, exogenous IL-2 mRNA could no longer be detected in the peripheral whole blood 48 hours after Vero-IL-2 cell administration. In addition, we did not find any expression of exogenous IL-2 mRNA in post-therapeutic lesions removed 29 days after the start of therapy. A major finding of this trial concerns the two histological responses of two treated subcutaneous nodules not associated with an apparent clinical response. The relationship between local treatment and tumour regression was supported by replacement of tumour cells by inflammatory cells in regressing lesions and marked induction of T and natural killer cell derived cytokines (IL-2, IL-4, IFNg …) in post-therapeutic lesions analysed 28 days after the start of Vero-IL-2 administration. Gene therapy using xenogeneic cells as vehicle may therefore present certain advantages over other vectors, such as its complete absence of toxicity. Furthermore, the in vivo biological effect of immunostimulatory genes, i.e IL-2-, may be potentiated by the xenogeneic rejection reaction. © 2000 Cancer Research Campaign http://www.bjcancer.com

Keywords: xenogeneic cells, interleukin-2, T cell activation, cytokine subcutaneous metastasis

Full Text

The Full Text of this article is available as a PDF (392.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Addison C. L., Braciak T., Ralston R., Muller W. J., Gauldie J., Graham F. L. Intratumoral injection of an adenovirus expressing interleukin 2 induces regression and immunity in a murine breast cancer model. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8522–8526. doi: 10.1073/pnas.92.18.8522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aruga A., Aruga E., Chang A. E. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant. Cancer Res. 1997 Aug 1;57(15):3230–3237. [PubMed] [Google Scholar]
  3. Berd D., Kairys J., Dunton C., Mastrangelo M. J., Sato T., Maguire H. C., Jr Autologous, hapten-modified vaccine as a treatment for human cancers. Semin Oncol. 1998 Dec;25(6):646–653. [PubMed] [Google Scholar]
  4. Bowman L. C., Grossmann M., Rill D., Brown M., Zhong W. Y., Alexander B., Leimig T., Coustan-Smith E., Campana D., Jenkins J. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998 Jun 10;9(9):1303–1311. doi: 10.1089/hum.1998.9.9-1303. [DOI] [PubMed] [Google Scholar]
  5. Bubenik J., Voitenok N. N., Kieler J., Prassolov V. S., Chumakov P. M., Bubenikova D., Simova J., Jandlova T. Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett. 1988 Dec;19(4):279–282. doi: 10.1016/0165-2478(88)90155-1. [DOI] [PubMed] [Google Scholar]
  6. Chen L. Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today. 1998 Jan;19(1):27–30. doi: 10.1016/s0167-5699(97)01180-8. [DOI] [PubMed] [Google Scholar]
  7. Chouaib S., Asselin-Paturel C., Mami-Chouaib F., Caignard A., Blay J. Y. The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today. 1997 Oct;18(10):493–497. doi: 10.1016/s0167-5699(97)01115-8. [DOI] [PubMed] [Google Scholar]
  8. Clary B. M., Coveney E. C., Philip R., Blazer D. G., 3rd, Morse M., Gilboa E., Lyerly H. K. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells. Cancer Gene Ther. 1997 Mar-Apr;4(2):97–104. [PubMed] [Google Scholar]
  9. Cordier L., Duffour M. T., Sabourin J. C., Lee M. G., Cabannes J., Ragot T., Perricaudet M., Haddada H. Complete recovery of mice from a pre-established tumor by direct intratumoral delivery of an adenovirus vector harboring the murine IL-2 gene. Gene Ther. 1995 Jan;2(1):16–21. [PubMed] [Google Scholar]
  10. Cressent M., Pidoux E., Cohen R., Modigliani E., Roth C. Interleukin-2 and interleukin-4 display potent antitumour activity on rat medullary thyroid carcinoma cells. Eur J Cancer. 1995 Dec;31A(13-14):2379–2384. doi: 10.1016/0959-8049(95)00445-9. [DOI] [PubMed] [Google Scholar]
  11. Dorval T., Mathiot C., Chosidow O., Revuz J., Avril M. F., Guillaume J. C., Tursz T., Brandely M., Pouillart P., Fridman W. H. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters. Biotechnol Ther. 1992;3(1-2):63–79. [PubMed] [Google Scholar]
  12. Dow S. W., Elmslie R. E., Willson A. P., Roche L., Gorman C., Potter T. A. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest. 1998 Jun 1;101(11):2406–2414. doi: 10.1172/JCI510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539–3543. doi: 10.1073/pnas.90.8.3539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Elkins K. L., Ennist D. L., Winegar R. K., Weir J. P. In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice. Hum Gene Ther. 1994 Jul;5(7):809–820. doi: 10.1089/hum.1994.5.7-809. [DOI] [PubMed] [Google Scholar]
  15. Fakhrai H., Shawler D. L., Gjerset R., Naviaux R. K., Koziol J., Royston I., Sobol R. E. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther. 1995 May;6(5):591–601. doi: 10.1089/hum.1995.6.5-591. [DOI] [PubMed] [Google Scholar]
  16. Fearon E. R., Itaya T., Hunt B., Vogelstein B., Frost P. Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res. 1988 Jun 1;48(11):2975–2980. [PubMed] [Google Scholar]
  17. Fearon E. R., Pardoll D. M., Itaya T., Golumbek P., Levitsky H. I., Simons J. W., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990 Feb 9;60(3):397–403. doi: 10.1016/0092-8674(90)90591-2. [DOI] [PubMed] [Google Scholar]
  18. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990 Oct 1;172(4):1217–1224. doi: 10.1084/jem.172.4.1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Gemlo B. T., Palladino M. A., Jr, Jaffe H. S., Espevik T. P., Rayner A. A. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988 Oct 15;48(20):5864–5867. [PubMed] [Google Scholar]
  20. Ghosh P., Komschlies K. L., Cippitelli M., Longo D. L., Subleski J., Ye J., Sica A., Young H. A., Wiltrout R. H., Ochoa A. C. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst. 1995 Oct 4;87(19):1478–1483. doi: 10.1093/jnci/87.19.1478. [DOI] [PubMed] [Google Scholar]
  21. Glick R. P., Lichtor T., Mogharbel A., Taylor C. A., Cohen E. P. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma. Neurosurgery. 1997 Oct;41(4):898–907. doi: 10.1097/00006123-199710000-00025. [DOI] [PubMed] [Google Scholar]
  22. Golumbek P. T., Azhari R., Jaffee E. M., Levitsky H. I., Lazenby A., Leong K., Pardoll D. M. Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res. 1993 Dec 15;53(24):5841–5844. [PubMed] [Google Scholar]
  23. Golumbek P. T., Lazenby A. J., Levitsky H. I., Jaffee L. M., Karasuyama H., Baker M., Pardoll D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991 Nov 1;254(5032):713–716. doi: 10.1126/science.1948050. [DOI] [PubMed] [Google Scholar]
  24. Haddada H., Ragot T., Cordier L., Duffour M. T., Perricaudet M. Adenoviral interleukin-2 gene transfer into P815 tumor cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther. 1993 Dec;4(6):703–711. doi: 10.1089/hum.1993.4.6-703. [DOI] [PubMed] [Google Scholar]
  25. Heo D. S., Yoon S. J., Kim W. S., Lee K. H., Seol J. G., Lee S. G., Jung C. W., Cho E. K., Kim C. W., Park M. H. Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/beta2-microglobulin gene in patients with cancer. Hum Gene Ther. 1998 Sep 20;9(14):2031–2038. doi: 10.1089/hum.1998.9.14-2031. [DOI] [PubMed] [Google Scholar]
  26. Janeway C. A., Jr, Bottomly K. Signals and signs for lymphocyte responses. Cell. 1994 Jan 28;76(2):275–285. doi: 10.1016/0092-8674(94)90335-2. [DOI] [PubMed] [Google Scholar]
  27. Keilholz U., Scheibenbogen C., Stoelben E., Saeger H. D., Hunstein W. Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Eur J Cancer. 1994;30A(7):955–958. doi: 10.1016/0959-8049(94)90122-8. [DOI] [PubMed] [Google Scholar]
  28. Konrad M. W., Hemstreet G., Hersh E. M., Mansell P. W., Mertelsmann R., Kolitz J. E., Bradley E. C. Pharmacokinetics of recombinant interleukin 2 in humans. Cancer Res. 1990 Apr 1;50(7):2009–2017. [PubMed] [Google Scholar]
  29. Koppenhagen F. J., Küpcü Z., Wallner G., Crommelin D. J., Wagner E., Storm G., Kircheis R. Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells. Clin Cancer Res. 1998 Aug;4(8):1881–1886. [PubMed] [Google Scholar]
  30. Leroy P., Slos P., Homann H., Erbs P., Poitevin Y., Regulier E., Colonna F. Q., Devauchelle P., Roth C., Pavirani A. Cancer immunotherapy by direct in vivo transfer of immunomodulatory genes. Res Immunol. 1998 Sep-Oct;149(7-8):681–684. doi: 10.1016/s0923-2494(99)80038-8. [DOI] [PubMed] [Google Scholar]
  31. Lindenmann J., Klein P. A. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med. 1967 Jul 1;126(1):93–108. doi: 10.1084/jem.126.1.93. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Lotze M. T., Custer M. C., Sharrow S. O., Rubin L. A., Nelson D. L., Rosenberg S. A. In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. Cancer Res. 1987 Apr 15;47(8):2188–2195. [PubMed] [Google Scholar]
  33. Maass G., Schmidt W., Berger M., Schilcher F., Koszik F., Schneeberger A., Stingl G., Birnstiel M. L., Schweighoffer T. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5540–5544. doi: 10.1073/pnas.92.12.5540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Mir L. M., Roth C., Orlowski S., Quintin-Colonna F., Fradelizi D., Belehradek J., Jr, Kourilsky P. Systemic antitumor effects of electrochemotherapy combined with histoincompatible cells secreting interleukin-2. J Immunother Emphasis Tumor Immunol. 1995 Jan;17(1):30–38. doi: 10.1097/00002371-199501000-00004. [DOI] [PubMed] [Google Scholar]
  35. Mukherji B., Chakraborty N. G. Immunobiology and immunotherapy of melanoma. Curr Opin Oncol. 1995 Mar;7(2):175–184. doi: 10.1097/00001622-199503000-00014. [DOI] [PubMed] [Google Scholar]
  36. Pardoll D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol. 1995;13:399–415. doi: 10.1146/annurev.iy.13.040195.002151. [DOI] [PubMed] [Google Scholar]
  37. Plautz G. E., Yang Z. Y., Wu B. Y., Gao X., Huang L., Nabel G. J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4645–4649. doi: 10.1073/pnas.90.10.4645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Quintin-Colonna F., Devauchelle P., Fradelizi D., Mourot B., Faure T., Kourilsky P., Roth C., Mehtali M. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2. Gene Ther. 1996 Dec;3(12):1104–1112. [PubMed] [Google Scholar]
  39. Rochlitz C., Jantscheff P., Bongartz G., Dietrich P. Y., Quiquerez A. L., Schatz C., Mehtali M., Courtney M., Tartour E., Dorval T. Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors. Cancer Gene Ther. 1999 May-Jun;6(3):271–281. doi: 10.1038/sj.cgt.7700047. [DOI] [PubMed] [Google Scholar]
  40. Roth C., Mir L. M., Cressent M., Quintin-Colonna F., Ley V., Fradelizi D., Kourilsky P. Inhibition of tumor growth by histoincompatible cells expressing interleukin-2. Int Immunol. 1992 Dec;4(12):1429–1436. doi: 10.1093/intimm/4.12.1429. [DOI] [PubMed] [Google Scholar]
  41. Schaafsma M. R., Falkenburg J. H., Landegent J. E., Duinkerken N., Osanto S., Ralph P., Kaushansky K., Wagemaker G., Van Damme J., Willemze R. In vivo production of interleukin-5, granulocyte-macrophage colony-stimulating factor, macrophages colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood. 1991 Oct 15;78(8):1981–1987. [PubMed] [Google Scholar]
  42. Schmidt-Wolf G. D., Schmidt-Wolf I. G. Cytokines and gene therapy. Immunol Today. 1995 Apr;16(4):173–175. doi: 10.1016/0167-5699(95)80116-2. [DOI] [PubMed] [Google Scholar]
  43. Schüler T., Qin Z., Ibe S., Noben-Trauth N., Blankenstein T. T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice. J Exp Med. 1999 Mar 1;189(5):803–810. doi: 10.1084/jem.189.5.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Speiser D. E., Miranda R., Zakarian A., Bachmann M. F., McKall-Faienza K., Odermatt B., Hanahan D., Zinkernagel R. M., Ohashi P. S. Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med. 1997 Aug 29;186(5):645–653. doi: 10.1084/jem.186.5.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Tahara H., Zeh H. J., 3rd, Storkus W. J., Pappo I., Watkins S. C., Gubler U., Wolf S. F., Robbins P. D., Lotze M. T. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994 Jan 1;54(1):182–189. [PubMed] [Google Scholar]
  46. Tartour E., Fridman W. H. Cytokines and cancer. Int Rev Immunol. 1998;16(5-6):683–704. doi: 10.3109/08830189809043014. [DOI] [PubMed] [Google Scholar]
  47. Tartour E., Gey A., Sastre-Garau X., Lombard Surin I., Mosseri V., Fridman W. H. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst. 1998 Feb 18;90(4):287–294. doi: 10.1093/jnci/90.4.287. [DOI] [PubMed] [Google Scholar]
  48. Tartour E., Mathiot C., Fridman W. H. Current status of interleukin-2 therapy in cancer. Biomed Pharmacother. 1992;46(10):473–484. doi: 10.1016/0753-3322(92)90005-r. [DOI] [PubMed] [Google Scholar]
  49. Tepper R. I., Pattengale P. K., Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell. 1989 May 5;57(3):503–512. doi: 10.1016/0092-8674(89)90925-2. [DOI] [PubMed] [Google Scholar]
  50. Tsai S. C., Gansbacher B., Tait L., Miller F. R., Heppner G. H. Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J Natl Cancer Inst. 1993 Apr 7;85(7):546–553. doi: 10.1093/jnci/85.7.546. [DOI] [PubMed] [Google Scholar]
  51. Veelken H., Mackensen A., Lahn M., Köhler G., Becker D., Franke B., Brennscheidt U., Kulmburg P., Rosenthal F. M., Keller H. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int J Cancer. 1997 Jan 27;70(3):269–277. doi: 10.1002/(sici)1097-0215(19970127)70:3<269::aid-ijc4>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  52. Vowels B. R., Lessin S. R., Cassin M., Jaworsky C., Benoit B., Wolfe J. T., Rook A. H. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol. 1994 Nov;103(5):669–673. doi: 10.1111/1523-1747.ep12398454. [DOI] [PubMed] [Google Scholar]
  53. Wang Q., Stanley J., Kudoh S., Myles J., Kolenko V., Yi T., Tubbs R., Bukowski R., Finke J. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol. 1995 Aug 1;155(3):1382–1392. [PubMed] [Google Scholar]
  54. Zatloukal K., Schneeberger A., Berger M., Schmidt W., Koszik F., Kutil R., Cotten M., Wagner E., Buschle M., Maass G. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters. J Immunol. 1995 Apr 1;154(7):3406–3419. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES